Hormonal
GLP-1 receptor agonists (specifically liraglutide, semaglutide, and tirzepatide) are primarily utilized in clinical practice for obesity treatment rather than type 2 diabetes, with obesity being the dominant indication across these agents.
If you are using GLP-1 medications like Ozempic, Wegovy, or Mounjaro, you are part of a large group using them primarily for weight management, not just blood sugar control. If you dislike injections, ask about oral semaglutide. Be aware that newer drugs like Tirzepatide may be expensive and not covered by insurance, which can lead to stopping treatment early.
These results indicate that, regardless of registration differences, obesity was the dominant area of application for these drugs in everyday medical practice.
Why this rating
Large retrospective cohort study (n=36,399) with statistically significant results, though observational.
Source
Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland
Klaudia Nowak et al. · Healthcare · 2025
DOI 10.3390/healthcare13222874
More from this paper
- Tirzepatide demonstrates superior weight loss efficacy compared to Semaglutide, achieving an average weight loss of -20.9% at the highest dose (15 mg) in obese patients without type 2 diabetes.Strong
- Oral semaglutide is increasingly preferred by younger female patients with fewer comorbidities compared to subcutaneous semaglutide.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →